dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study Differences between GLP-1 receptor agonists

GLP-1 medications change how your body processes food, and they also shift the way you experience hunger and fullness

Industry analysts, including GlobalData, predict FDA approval for retatrutide in 2027, with a projected sales forecast of $15.6 billion by 2031

Common side effects include nausea, vomiting, diarrhea, constipation, headaches and injection site reactions (redness, swelling, irritation)

Cardiovascular exercise supports caloric deficit and cardiovascular health without the muscle-preserving benefits of resistance training

See what a new study found in the Memory and Cognition section of the Dark Chocolate and Cocoa Review